Ignis Therapeutics Funding: $185M Raised, Series A (2021)
Ignis Therapeutics is based in Shanghai, China. It has raised $185M in total funding. Latest round: Series A.
Ignis Therapeutics funding overview
Ignis Therapeutics is based in Shanghai, China. Ignis Therapeutics has raised $185M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in November 2021. The round record for Ignis Therapeutics runs through 2021; nothing later has been disclosed. Investors on record include 6 Dimensions Capital, SK Biopharmaceuticals, Ruentex Group, KB Investment, Mubadala Investment Company, HBM Healthcare Investments and 1 others. 7 distinct backers are named across the disclosed rounds.
Ignis Therapeutics has raised $185M in total disclosed funding across the rounds on record.
Who has invested in Ignis Therapeutics?
6 Dimensions Capital, SK Biopharmaceuticals, Ruentex Group, KB Investment, Mubadala Investment Company, HBM Healthcare Investments are named among the investors backing Ignis Therapeutics.
What was the latest Ignis Therapeutics funding round?
The most recent disclosed round is a Series A, announced in November 2021.
Where is Ignis Therapeutics based?
Ignis Therapeutics is based in Shanghai, China.
When did Ignis Therapeutics last raise?
The last disclosed Ignis Therapeutics round closed in November 2021 at Series A.
Ignis Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Shanghai below to benchmark round size and investor mix.
